Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Feb;24(2):378-384.
doi: 10.1002/ejhf.2376. Epub 2021 Nov 21.

Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT

João Pedro Ferreira  1 , Jiankang Liu  2 , Brian L Claggett  2 , Orly Vardeny  3 , Bertram Pitt  4 , Marc A Pfeffer  2 , Scott D Solomon  2 , Faiez Zannad  1
Affiliations
Free article
Randomized Controlled Trial

Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT

João Pedro Ferreira et al. Eur J Heart Fail. 2022 Feb.
Free article

Abstract

Aims: Outpatient treatment for the worsening of signs and symptoms of heart failure (HF) is usually not incorporated in the main outcomes of HF trials. Patients with HF and a preserved ejection fraction (HFpEF) may experience frequent episodes of outpatient worsening HF. The aim of this study was to evaluate the frequency, prognostic impact, and the effect of spironolactone on outpatient diuretic intensification (ODI), among 1767 patients enrolled in TOPCAT-Americas.

Methods and results: Time-updated Cox models and win ratio analysis. ODI was defined by a post-randomization loop diuretic dose increase or new initiation. The median follow-up was 2.9 years. At baseline, 1362 (77%) patients were taking loop diuretics. During the follow-up, 685 (38.8%) patients experienced ODI, which was associated with a higher risk of subsequent cardiovascular events and death [adjusted hazard ratio (HR) for HF hospitalization or cardiovascular death 1.67, 95% confidence interval (CI) 1.36-2.04; HR for cardiovascular death 2.17, 95% CI 1.64-2.87); and HR for all-cause mortality 1.75, 95% CI 1.41-2.16] (p < 0.001 for all outcomes). Adding ODI to the composite of HF hospitalization or cardiovascular death increased the event rate by three-fold in the placebo group (from 10.4 to 29.9 events per 100 person-years). Spironolactone treatment led to a 26% relative reduction of the extended composite of ODI or HF hospitalization or cardiovascular death (HR 0.74, 95% CI 0.65-0.85; p < 0.001) compared with a 16% relative reduction of HF hospitalization or cardiovascular death (HR 0.84, 95% CI 0.70-0.99; p = 0.044). Using win ratio provided similar estimates.

Conclusion: In HFpEF, ODI was frequent and independently associated with subsequent cardiovascular events. Spironolactone significantly reduced an extended composite outcome incorporating ODI.

Keywords: Expanded outcomes; Heart failure with preserved ejection fraction; Outpatient diuretic intensification; Spironolactone; Treatment effect.

PubMed Disclaimer

References

    1. Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3(3):252-9.
    1. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2020;143(4):326-36.
    1. Ferreira JP, Rossignol P, Dewan P, Lamiral Z, White WB, Pitt B, et al. Income level and inequality as complement to geographical differences in cardiovascular trials. Am Heart J. 2019;218:66-74.
    1. Goyal P, Almarzooq ZI, Horn EM, Karas MG, Sobol I, Swaminathan RV, et al. Characteristics of hospitalizations for heart failure with preserved ejection fraction. Am J Med. 2016;129(6):e15-26.635.
    1. Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, et al. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2018;21(1):112-20.

Publication types

MeSH terms

Substances